BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 9.4% – Here’s Why

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) dropped 9.4% during mid-day trading on Wednesday . The company traded as low as $8.17 and last traded at $8.03. 123,171 shares changed hands during trading, a decline of 65% from the average daily volume of 348,500 shares. The stock had previously closed at $8.86.

Wall Street Analyst Weigh In

Several research firms have recently commented on BBOT. JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Oppenheimer assumed coverage on BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price for the company. Wall Street Zen upgraded BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Leerink Partners reduced their target price on BridgeBio Oncology Therapeutics to $27.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Oncology Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $23.12.

BridgeBio Oncology Therapeutics Stock Performance

The business’s 50 day moving average price is $8.72 and its 200-day moving average price is $8.70. The firm has a market capitalization of $442.54 million, a PE ratio of -2.00 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. As a group, analysts anticipate that BridgeBio Oncology Therapeutics, Inc will post -2.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BBOT. CIBC Private Wealth Group LLC acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth about $63,000. Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC purchased a new stake in BridgeBio Oncology Therapeutics during the fourth quarter worth about $144,000. Quadrature Capital Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the fourth quarter worth about $162,000. Finally, BIT Capital GmbH acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $313,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.